Although the third generation EGFR third generation EGFR tyrosine kinase inhibitor (TKI) osimertinib has improved the outcome for many patients with NSCLC tumours driven by mutated EGFR and with advanced disease, emerging treatment resistance is still a major clinical dilemma. This evidence concerns the gene EGFR and non-small cell lung carcinoma.